Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum
International Journal of Technology Assessment in Health Care · 2025
DOI: 10.1017/s0266462325100172 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Technology Assessment in Health Care, 2025. Verfasst von Megan Wiggins und 2 weiteren Autor:innen. Beteiligte Einrichtung: https://ror.org/03e81x648Institute of Health Economics, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cost-Benefit Analysis, Continuity of Patient Care, Models, Economic. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Health Services.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objectives
The aim of this study is to develop a patient-level model for type 2 diabetes mellitus (T2DM) progression that can estimate the cost-effectiveness of T2DM interventions from prevention to management.
Methods
We developed an individual-level microsimulation model, the Institute of Health Economics Diabetes Model (IHE-DM), that simulates: (i) T2DM progression from normal glucose tolerance (NGT) to T2DM, (ii) the occurrence and timing of eight comorbidities and death, and (iii) the correlated progression of risk factors over time. We report model validation and use a case study to investigate the cost-effectiveness of a hypothetical T2DM prevention program.
Results
The internal validation indicated excellent performance with mean absolute differences between the predicted and observed values for all endpoints of less than 1 percent. External validation results were mixed. The model under-predicted cumulative T2DM incidence in the first 8 years, predicted well from years eight through eleven, and over-predicted from years twelve through fifteen. Our case study estimated an incremental net monetary benefit of CAD 2,701 (USD 2,289) (95% Uncertainty Interval: CAD 1,316 to 4,000 [USD 1,115 to 3,390]) over the 15-year time horizon.
Conclusions
Prominent T2DM models focus on patients with diagnosed T2DM whereas our model simulates progression from NGT to T2DM and incorporates important correlations in the progression of risk factors. These adaptations allow us to evaluate preventative interventions and better capture the long-term impacts, filling an important gap in the evidence base. Our model can be used to inform future funding decisions for T2DM interventions across the care continuum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- https://ror.org/03e81x648Institute of Health Economics, Edmonton, AB, Canada.
- Faculty of Medicine and Dentistry, https://ror.org/0160cpw27University of Alberta, Edmonton, AB, Canada.
- Health Organisation, Policy, and Economics, School of Health Sciences, https://ror.org/027m9bs27University of Manchester, Manchester, UK.
ORCID-Profile: Megan Wiggins, Jeff Round
Förderung
- Alberta Health Services
Zitieren
APA
Wiggins, M., Round, J., & Kirwin, E. (2025). Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325100172
Vancouver
Wiggins M, Round J, Kirwin E. Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum. International Journal of Technology Assessment in Health Care. 2025. doi:10.1017/s0266462325100172
BibTeX
@article{Wiggins2025,
author = {Wiggins, Megan and Round, Jeff and Kirwin, Erin},
title = {Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum},
journal = {International Journal of Technology Assessment in Health Care},
year = {2025},
doi = {10.1017/s0266462325100172}
}
EUVIMED